Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Omeros: Ophthalmology Drug OMS302 Met Primary, Secondary Goals In Phase 3 Trial

3/13/2012 7:23 AM ET

Omeros Corp. (OMER: Quote) said its ophthalmology product OMS302 met its primary and secondary end points in Phase 3 clinical trial in patients undergoing intraocular lens replacement surgery.

According to the company, OMS302 achieved its primary endpoint by demonstrating statistically significant maintenance of intraoperative mydriasis, also called pupil dilation. OMS302 also showed statistical superiority over placebo in reduction of pain in the early postoperative period. The data for both endpoints are clinically meaningful.

OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery.

"...This achievement marks our transition to a company preparing, rather than hoping, to commercialize our first product," said Gregory Demopulos, chairman and chief executive officer of Omeros. "Following our recent successful meetings with U.S. and European regulators, we plan to begin enrolling patients in our second Phase 3 trial early next month and to submit marketing applications in both the U.S. and Europe in the first part of 2013."

Register
To receive FREE breaking news email alerts for Omeros Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Housing starts in the U.S. showed a notable increase in the month of March, according to a report released by the Commerce Department on Wednesday, although starts still came in well below economist estimates. The report showed that housing starts climbed 2.8 percent to an annual rate of 946,000 in March from the revised February estimate of 920,000. After moving mostly higher over the course of the two previous sessions, stocks may see some further upside in early trading on Wednesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 63 points. The U.K. unemployment rate fell below the 7 percent threshold to a five-year low in February and average earnings finally moved above inflation reducing the squeeze on household finances. The jobless rate came in at 6.9 percent of the labor force, the lowest since February 2009, data from the Office for National Statistics showed Wednesday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.